Cargando…
P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430666/ http://dx.doi.org/10.1097/01.HS9.0000847820.72232.2a |
| _version_ | 1784779837057007616 |
|---|---|
| author | Bachy, E. Savage, K. J. Huang, H. Kwong, Y. L. Gritti, G. Zhang, Q. Liberati, A. M. Cao, J. Yang, H. Hao, S. Hu, J. Zhou, K. Russo, F. Zhang, H. Sang, W. Ji, J. Ferreri, A. J. M. Damaj, G. L. Liu, H. Zhang, W. Ke, X. Ghiggi, C. Huang, S. Li, X. Yao, H. Paik, J. Novotny, W. Zhou, W. Zhu, H. Huang, J. Zinzani, P. L. |
| author_facet | Bachy, E. Savage, K. J. Huang, H. Kwong, Y. L. Gritti, G. Zhang, Q. Liberati, A. M. Cao, J. Yang, H. Hao, S. Hu, J. Zhou, K. Russo, F. Zhang, H. Sang, W. Ji, J. Ferreri, A. J. M. Damaj, G. L. Liu, H. Zhang, W. Ke, X. Ghiggi, C. Huang, S. Li, X. Yao, H. Paik, J. Novotny, W. Zhou, W. Zhu, H. Huang, J. Zinzani, P. L. |
| author_sort | Bachy, E. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430666 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94306662022-08-31 P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY Bachy, E. Savage, K. J. Huang, H. Kwong, Y. L. Gritti, G. Zhang, Q. Liberati, A. M. Cao, J. Yang, H. Hao, S. Hu, J. Zhou, K. Russo, F. Zhang, H. Sang, W. Ji, J. Ferreri, A. J. M. Damaj, G. L. Liu, H. Zhang, W. Ke, X. Ghiggi, C. Huang, S. Li, X. Yao, H. Paik, J. Novotny, W. Zhou, W. Zhu, H. Huang, J. Zinzani, P. L. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430666/ http://dx.doi.org/10.1097/01.HS9.0000847820.72232.2a Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Bachy, E. Savage, K. J. Huang, H. Kwong, Y. L. Gritti, G. Zhang, Q. Liberati, A. M. Cao, J. Yang, H. Hao, S. Hu, J. Zhou, K. Russo, F. Zhang, H. Sang, W. Ji, J. Ferreri, A. J. M. Damaj, G. L. Liu, H. Zhang, W. Ke, X. Ghiggi, C. Huang, S. Li, X. Yao, H. Paik, J. Novotny, W. Zhou, W. Zhu, H. Huang, J. Zinzani, P. L. P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY |
| title | P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY |
| title_full | P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY |
| title_fullStr | P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY |
| title_full_unstemmed | P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY |
| title_short | P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY |
| title_sort | p1239: tislelizumab, a pd-1 inhibitor for relapsed/refractory mature t- and nk-cell neoplasms: results from a phase 2 study |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430666/ http://dx.doi.org/10.1097/01.HS9.0000847820.72232.2a |
| work_keys_str_mv | AT bachye p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT savagekj p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT huangh p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT kwongyl p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT grittig p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zhangq p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT liberatiam p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT caoj p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT yangh p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT haos p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT huj p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zhouk p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT russof p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zhangh p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT sangw p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT jij p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT ferreriajm p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT damajgl p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT liuh p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zhangw p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT kex p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT ghiggic p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT huangs p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT lix p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT yaoh p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT paikj p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT novotnyw p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zhouw p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zhuh p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT huangj p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study AT zinzanipl p1239tislelizumabapd1inhibitorforrelapsedrefractorymaturetandnkcellneoplasmsresultsfromaphase2study |